Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Rac family small GTPases, primarily comprising Rac1, Rac2, and Rac3, are essential members of the Rho family of small G proteins that act as molecular switches in intracellular signaling pathways [1, 12]. These proteins cycle between an inactive GDP-bound state and an active GTP-bound state, a transition facilitated by guanine nucleotide exchange factors (GEFs) and terminated by GTPase-activating proteins (GAPs) [1, 16]. Biologically, Rac GTPases are master regulators of the actin cytoskeleton, where they drive the formation of lamellipodia and membrane ruffles to facilitate cell migration and adhesion [5, 15]. Beyond structural roles, they are involved in cell cycle progression, gene expression, and the activation of the NADPH oxidase complex to generate reactive oxygen species (ROS) [1, 11]. In clinical contexts, the dysregulation or hyperactivation of Rac proteins is a hallmark of various cancers, contributing significantly to tumor invasion, metastasis, and therapeutic resistance [5, 9]. Because of their central role in oncogenic signaling, Rac family members are prominent therapeutic targets, with drug development efforts focusing on small molecules that inhibit GEF-mediated activation or disrupt interactions with downstream effectors like PAK1 [5, 17, 18]. However, targeting Rac presents challenges due to its broad involvement in normal physiological processes, including immune cell function and glucose metabolism [12, 16]. Recent research also suggests that Rac hyperactivation may be linked to neurodevelopmental disorders and cognitive processes such as active forgetting [1, 10]. Therapeutic strategies also include targeting post-translational modifications, such as geranylgeranylation, which is required for Rac membrane localization and activity [4, 6]. Despite the promise of Rac inhibitors in preclinical models, achieving high selectivity and minimizing systemic toxicity remains a significant hurdle for clinical translation [5, 17].
Inhibition of guanine nucleotide exchange factor (GEF) interaction, displacement of guanine nucleotides, and inhibition of downstream effector binding or post-translational modification.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras-related C3 botulinum toxin substrate (Rac) (Rac).